304896-28-4

Basic information

• Product Name: 2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide
• Synonyms: 2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide;AGK2;SIRT2 Inhibitor, AGK2;2-Cyano-3-(5-(2,5-dichlorophenyl)furan-2-yl)-N-(quinolin-5-yl)acrylamide
• CAS NO: 304896-28-4
• Molecular Formula: C23H13Cl2N3O2
• Molecular Weight: 434.27
• Product Categories: Inhibitors
• Mol File: 304896-28-4.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 675.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.445±0.06 g/cm3(Predicted)
• Storage Temp.: Room temp
• Solubility: DMSO: soluble2mg/mL, clear (warmed)
• PKA: 8.87±0.43(Predicted)
• CAS DataBase Reference: 2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide(304896-28-4)
• EPA Substance Registry System: 2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide(304896-28-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 304896-28-4(Hazardous Substances Data)

Usage

Description

2-Cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide, also known as AGK2, is a small molecule compound that acts as a selective inhibitor of the sirtuin family of proteins, specifically targeting SIRT2. It has been extensively studied for its potential therapeutic applications in various diseases and conditions.

Uses

Used in Neurodegenerative Disease Research:
AGK2 is used as a SIRT2 inhibitor in neurodegenerative disease research, particularly in Parkinson's disease models. It has been shown to rescue dopamine neurons from α-synuclein toxicity, which is a key pathological feature of Parkinson's disease. The inhibition of SIRT2 by AGK2 leads to cell death and a decrease in intracellular ATP levels, which may contribute to its neuroprotective effects.
Used in Cancer Research:
AGK2 is also used as a SIRT2 inhibitor in cancer research. The inhibition of SIRT2 by AGK2 has been shown to induce cell death and decrease intracellular ATP levels in cancer cells, suggesting its potential as a therapeutic agent for cancer treatment. Further research is needed to explore the specific mechanisms by which AGK2 exerts its anti-cancer effects and to determine its efficacy and safety in clinical settings.
Used in Drug Development:
AGK2 is used as a lead compound in drug development efforts targeting SIRT2 for the treatment of various diseases and conditions. Its selectivity for SIRT2 and its ability to induce cell death and decrease intracellular ATP levels make it a promising candidate for the development of new therapeutic agents. Further optimization and modification of AGK2's chemical structure may be necessary to improve its pharmacokinetic properties and therapeutic potential.

Biological Activity

Selective inhibitor of SIRT2 (IC 50 = 3.5 μ M). Displays no activity at SIRT1 and SIRT3 at concentrations up to 40 μ M. Reduces α -synuclein-mediated toxicity in in vitro and in vivo models of Parkinson's disease.

Biochem/physiol Actions

AGK2 is a SIRT2 inhibitor. AGK2 rescues dopamine neurons from α-synuclein toxicity in Parkinson′s disease models. IC50 for SIRT2 = 3.5 uM. AGK2 is >15-fold more selective for SIRT2 than SIRT1 and SIRT3. AGK2 may be the most selective SIRT2 inhibitor available.

references

[1]. outeiro tf, kontopoulos e, altmann sm, et al. sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of parkinson's disease. science, 2007, 317(5837): 516-519. [2]. scuderi c, stecca c, bronzuoli mr, et al. sirtuin modulators control reactive gliosis in an in vitro model of alzheimer's disease. front pharmacol, 2014, 5: 89.[3]. rotili d, tarantino d, nebbioso a, et al. discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. j med chem, 2012, 55(24): 10937-10947.